Skip to main content
Top
Literature
1.
go back to reference Henretig FM, Gribetz B, Kearney T, Lacouture P, Lovejoy FH (1988) Interpretation of color change in blood with varying degree of methemoglobinemia. J Toxicol Clin Toxicol 26:293–301CrossRefPubMed Henretig FM, Gribetz B, Kearney T, Lacouture P, Lovejoy FH (1988) Interpretation of color change in blood with varying degree of methemoglobinemia. J Toxicol Clin Toxicol 26:293–301CrossRefPubMed
3.
go back to reference Wilson SF, Tompson JM (eds) (1990) Respiratory disorders, vol 15. Mosby-Year Book, St. Louis Wilson SF, Tompson JM (eds) (1990) Respiratory disorders, vol 15. Mosby-Year Book, St. Louis
5.
go back to reference Rees SM, Nelson LS (2004) Dyshemoglobinemias. In: Tintinalli JE, Kelen GD, Stapczynski JS (eds) Emergency medicine—a comprehensive study guide, 6th edn. McGraw-Hill, New York, pp 1169–1171 Rees SM, Nelson LS (2004) Dyshemoglobinemias. In: Tintinalli JE, Kelen GD, Stapczynski JS (eds) Emergency medicine—a comprehensive study guide, 6th edn. McGraw-Hill, New York, pp 1169–1171
6.
go back to reference Food and Drug Administration (2011) FDA Drug Safety Communication: serious CNS reactions possible when methylene blue is given to patients taking certain psychiatric medications Food and Drug Administration (2011) FDA Drug Safety Communication: serious CNS reactions possible when methylene blue is given to patients taking certain psychiatric medications
Metadata
Title
Accidental Poisoning Resulting in Severe Methemoglobinemia in a 14-year-old Girl
Authors
A. K. Simalti
Manisha Naithani
Publication date
01-06-2016
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue Special Issue 1/2016
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-014-0455-4

Other articles of this Special Issue 1/2016

Indian Journal of Hematology and Blood Transfusion 1/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine